Floatz logo

271 assets in Renal Cell Carcinoma

Therapeutic assets addressing Renal Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Milademetan
Renal Cell Carcinoma
Rain Oncology IncP1/2D (30)
nir178
Renal Cell Carcinoma
Novartis PharmaceuticalsP2D (30)
Technetium Tc 99M Pentetate Sodium
Renal Cell Carcinoma
NYU Langone HealthN/AD (30)
Vobramitamab Duocarmazine
Renal Cell Carcinoma
MacroGenicsP1D (29)
13C-Fructose
Renal Cell Carcinoma
University of Texas Southwestern Medical CenterN/AD (28)
177lu-eb-psma-617
Renal Cell Carcinoma
Peking Union Medical College HospitalN/AD (28)
[68Ga]Ga-DOTA-CAIX peptide
Renal Cell Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyN/AD (28)
[68ga]ga-nota-cd70 antibody fragment
Renal Cell Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyN/AD (28)
[68ga]psma
Renal Cell Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyN/AD (28)
68ga-psma
Renal Cell Carcinoma
Peking Union Medical College HospitalN/AD (28)
Acetic-1-13C Acid
Renal Cell Carcinoma
University of Texas Southwestern Medical CenterN/AD (28)
Glucose, Anhydrous
Renal Cell Carcinoma
University of Texas Southwestern Medical CenterN/AD (28)
Glutamine
Renal Cell Carcinoma
University of Texas Southwestern Medical CenterN/AD (28)
Lactate
Renal Cell Carcinoma
University of Texas Southwestern Medical CenterN/AD (28)
exs74539
Renal Cell Carcinoma
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.P1NR ()
Imsa101
Renal Cell Carcinoma
University of Texas Southwestern Medical CenterP2NR ()
Phase 1A: Lb-Lr1109
Renal Cell Carcinoma
LG ChemP1NR ()
Rubidium (Rb-82)
Renal Cell Carcinoma
Assistance Publique - Hôpitaux de ParisP2NR ()
Slc-3010
Renal Cell Carcinoma
Yonsei UniversityP2NR ()
Showing 251 to 271 of 271 assets
PreviousPage 6 of 6Next